GENinCode Plc (LON:GENI – Get Free Report) dropped 7.1% on Thursday . The stock traded as low as GBX 0.86 and last traded at GBX 0.93. Approximately 3,936,327 shares changed hands during trading, a decline of 38% from the average daily volume of 6,329,568 shares. The stock had previously closed at GBX 1.
GENinCode Stock Down 7.1%
The company has a market cap of £6.74 million, a price-to-earnings ratio of -0.40 and a beta of 0.59. The business has a 50-day simple moving average of GBX 1.09 and a two-hundred day simple moving average of GBX 1.42. The company has a quick ratio of 15.88, a current ratio of 0.93 and a debt-to-equity ratio of 117.74.
GENinCode (LON:GENI – Get Free Report) last issued its quarterly earnings data on Monday, June 8th. The company reported GBX (2.08) EPS for the quarter. GENinCode had a negative net margin of 185.47% and a negative return on equity of 409.40%. The company had revenue of GBX 308 million for the quarter. As a group, equities analysts forecast that GENinCode Plc will post -7.1299999 earnings per share for the current fiscal year.
GENinCode Company Profile
GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.
GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.
GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.
Featured Articles
- Five stocks we like better than GENinCode
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for GENinCode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENinCode and related companies with MarketBeat.com's FREE daily email newsletter.
